NTG | Jotup

Qlaris Bio Completes $24 Million Series B Financing Round to Advance QLS‑111, a First-in-class Iop-lowering Drug Candidate for Glaucoma

Retrieved on:

Tuesday, April 30, 2024

Qlaris Bio, Inc. (“Qlaris”), a clinical-stage biotechnology company targeting unmet needs in debilitating ophthalmic diseases, today announced that it has closed a $24 million Series B financing round.

Key Points:

Qlaris Bio, Inc. (“Qlaris”), a clinical-stage biotechnology company targeting unmet needs in debilitating ophthalmic diseases, today announced that it has closed a $24 million Series B financing round.
Proceeds from the financing will support the continued clinical development of QLS‑111, a first-in-class therapeutic being developed to lower intraocular pressure (IOP) by targeting episcleral venous pressure (EVP).
“Qlaris is dedicated to developing new mechanisms of action that target unaddressed parameters within IOP regulation, an area of critical need.
Qlaris has the potential to demonstrate the importance of targeting EVP in the ongoing QLS‑111 Phase II trials and we look forward to the data from this innovative drug candidate.”

Qlaris Bio’s Novel IOP-Lowering Product, QLS‑111, is Dosed in Phase II Trials

Retrieved on:

Tuesday, April 2, 2024

Qlaris Bio, Inc. (“Qlaris”), a clinical-stage biotechnology company targeting unmet needs in debilitating ophthalmic diseases, today announced the initiation and dosing of two separate U.S.

Key Points:

Qlaris Bio, Inc. (“Qlaris”), a clinical-stage biotechnology company targeting unmet needs in debilitating ophthalmic diseases, today announced the initiation and dosing of two separate U.S.
Phase II masked, randomized clinical trials investigating QLS‑111 in patients with ocular hypertension and glaucoma.
“The start of these Phase II trials represents a key milestone in our goal of bringing QLS‑111 to glaucoma patients for whom consistent IOP lowering and control has been an unachievable goal,” said Thurein Htoo, Chief Executive Officer.
“IOP remains the only modifiable risk factor for the treatment of glaucoma, and additional treatments are needed for patients.

Blue Mantis Board Names Josh Dinneen as Next Chief Executive Officer – Long-Tenured CEO Ron Dupler to Become Chairman

Retrieved on:

Tuesday, November 14, 2023

Current CEO Ron Dupler will assume the role of Chairman and will remain a board member, devoting his time to supporting Dinneen and Blue Mantis customers and partners in a strategic advisory role.

Key Points:

Current CEO Ron Dupler will assume the role of Chairman and will remain a board member, devoting his time to supporting Dinneen and Blue Mantis customers and partners in a strategic advisory role.
“This is the perfect time for Josh Dinneen to become Blue Mantis’ next Chief Executive Officer.
We've selected a very strong and proven leader at a time when our company is well positioned for accelerating its growth,” said current Blue Mantis CEO Ron Dupler.
Partnering with Dupler and the Blue Mantis executive team, Dinneen has spearheaded the firm’s transformation from a solutions integration company to an award-winning MSP.

U.S. District Court for the Southern District of New York Rules That Certain Closed-End Funds, Including Funds Advised by BlackRock, Violated the Investment Company Act of 1940

Retrieved on:

Thursday, December 7, 2023

Saba filed its lawsuit in the Court on June 29, 2023 after the BlackRock trustees disclosed they would strip shareholders’ votes, in violation of the Investment Company Act of 1940 (the “ICA”), at their 2023 Annual Meeting.

Key Points:

Saba filed its lawsuit in the Court on June 29, 2023 after the BlackRock trustees disclosed they would strip shareholders’ votes, in violation of the Investment Company Act of 1940 (the “ICA”), at their 2023 Annual Meeting.
Despite the Funds filing various motions to dismiss the lawsuit, the Court ruled in favor of Saba, finding that the actions of the BlackRock Fund and its trustees violated federal law.
Just last week, the U.S. Court of Appeals for the Second Circuit upheld that certain Nuveen-advised closed-end funds also violated the ICA after Saba sued Nuveen and the trustees in the Court.
Royce Global Value Trust is managed by Royce Investment Partners, an affiliate of Franklin Templeton.

Photonic Technologies Introduce New Ways to Diagnose Menopause and Glaucoma

Retrieved on:

Monday, December 4, 2023

WASHINGTON, Dec. 4, 2023 /PRNewswire/ -- The Optica Foundation today released more detailed information on new women's health and vision research funded by the 2023 Optica Foundation Challenge. Researchers Samantha Grist, The University of British Columbia, Canada, and Fernando Zvietcovich, Pontificia Universidad Catolica del Peru, Peru, have proposed two separate light-based techniques to solve for challenges in diagnosing health-related concerns, specifically menopause and glaucoma.

Key Points:

Yet, despite the potential prevalence of menopause and its precursor perimenopause, physicians have limited tools and data to understand and predict symptoms or improve treatment.
However, new work from Samantha Grist, The University of British Columbia, Canada, offers promise in the form of a silicon photonic integrated circuit (PIC) with biosensors.
"Now, I'm really motivated to help people experiencing menopause diagnose and predict its stages and address its symptoms.
This grant gives me the chance to do meaningful work and demonstrate how photonic innovation can address unmet needs."

Transportation Insight & Nolan Transportation Group ranks fourth in 2023 top 100 Domestic Transportation Management (DTM) 3PLs list

Retrieved on:

Thursday, October 19, 2023

Associate, Transport, Research, NTG, A&A, Armstrong, TI, DTM, Longevity, Cargo

ATLANTA, Oct. 19, 2023 /PRNewswire/ -- Transportation Insight (TI) and Nolan Transportation Group (NTG), a leading provider of non-asset, tech-enabled logistics and brokerage solutions in North America, today announced it has achieved the number-four ranking on Armstrong & Associates, Inc. (A&A) 2023 Top 100 Domestic Transportation Management (DTM) 3PL providers list based on gross revenue.

Key Points:

ATLANTA, Oct. 19, 2023 /PRNewswire/ -- Transportation Insight (TI) and Nolan Transportation Group (NTG) , a leading provider of non-asset, tech-enabled logistics and brokerage solutions in North America, today announced it has achieved the number-four ranking on Armstrong & Associates, Inc. (A&A) 2023 Top 100 Domestic Transportation Management (DTM) 3PL providers list based on gross revenue.
Our experience and longevity in the industry have enabled us to create value for them through any cycle," said Ken Beyer, CEO, TI & NTG.
Companies surveyed and profiled for the list include global and regional 3PLs, digital freight brokers and freight forwarders, specialized/niche 3PLs, e-commerce fulfillment 3PLs, 3PL divisions within larger 3PLs and more.
See A&A's full Top 100 Domestic Transportation Management 3PL list here: Top 3PLs: A&A's Top 100 Domestic Transportation List .

May Institute Expert Offers Advice to Help Adults with Special Needs Who Also Have Dementia

Retrieved on:

Tuesday, September 26, 2023

RANDOLPH, Mass., Sept. 26, 2023 /PRNewswire/ -- According to the National Institutes of Health, dementia is the most feared condition for people over 65 and the second most feared condition, after cancer, among younger adults.

Key Points:

"Studies show that individuals with intellectual/developmental disability (IDD) are just as much at risk for developing dementia as the general population.
A national leader in providing evidence-based services for individuals across the lifespan with autism and other developmental disabilities, May Institute also serves a large number of adults with IDD.
Adapting activities to meet the needs and abilities of the individual and using simple one-step directions.
Founded more than 65 years ago, we provide a wide range of exceptional educational and rehabilitative services across the lifespan.

Transportation Insight and Nolan Transportation Group host Atlanta river cleanup with Chattahoochee Riverkeeper

Retrieved on:

Thursday, June 1, 2023

CRK, Tree, Upper Chattahoochee Riverkeeper, NTG, Atlanta Memorial Park, Work, Chattahoochee River

ATLANTA, June 1, 2023 /PRNewswire/ -- Transportation Insight (TI) and Nolan Transportation Group (NTG), a leading provider of non-asset, tech-enabled logistics and brokerage solutions in North America, will collaborate with Chattahoochee Riverkeeper (CRK) to remove trash in and around the Chattahoochee River watershed on June 3 at Atlanta Memorial Park. This marks the second consecutive year TI & NTG participate in a river cleanup event with CRK.

Key Points:

ATLANTA, June 1, 2023 /PRNewswire/ -- Transportation Insight (TI) and Nolan Transportation Group (NTG), a leading provider of non-asset, tech-enabled logistics and brokerage solutions in North America, will collaborate with Chattahoochee Riverkeeper (CRK) to remove trash in and around the Chattahoochee River watershed on June 3 at Atlanta Memorial Park.
This marks the second consecutive year TI & NTG participate in a river cleanup event with CRK.
TI & NTG partnered with environmental groups across the country to engage local offices in tree planting and river cleanup projects.
of debris from local waters through multiple river cleanup events.

GreenPages Promotes Chief Revenue Officer Joshua Dinneen to President

Retrieved on:

Wednesday, March 22, 2023

Strategic service management, NTG, CISO, G&A, Josh, Marketing, MSP, Dinneen, Acquisition, Investment, Growth, CIO, Management

PORTSMOUTH, N.H., March 22, 2023 (GLOBE NEWSWIRE) -- GreenPages, a nationally recognized leader in cloud and cybersecurity services, today announced the promotion of Chief Revenue Officer (CRO) Joshua (Josh) Dinneen to President.

Key Points:

PORTSMOUTH, N.H., March 22, 2023 (GLOBE NEWSWIRE) -- GreenPages, a nationally recognized leader in cloud and cybersecurity services, today announced the promotion of Chief Revenue Officer (CRO) Joshua (Josh) Dinneen to President.
He joined GreenPages as President of Strategic Services in 2018 following GreenPages’ acquisition of Norwell Technology Group (NTG), where Dinneen served as President and CEO.
A year later, Dinneen was named President of Sales and Marketing and in March of 2021, was promoted to CRO.
I look forward to our continued collaboration,”
As President, Dinneen is responsible for increasing GreenPages’ revenue streams and will assist Dupler in the areas of corporate development (M&A), strategy, investments, and innovation.

Qlaris Bio to Present at Glaucoma 360 New Horizons Forum

Retrieved on:

Friday, January 27, 2023

Qlaris Bio, Inc. , a biotechnology company targeting high unmet needs in debilitating ophthalmic diseases, announced today that Thurein Htoo, MS, MBA, the company’s co-founder and chief executive officer, will present during the 12th Annual Glaucoma 360 New Horizons Forum on Friday, Feb. 3, 2023, at 8:40 a.m. PT (11:40 a.m.

Key Points:

Qlaris Bio, Inc. , a biotechnology company targeting high unmet needs in debilitating ophthalmic diseases, announced today that Thurein Htoo, MS, MBA, the company’s co-founder and chief executive officer, will present during the 12th Annual Glaucoma 360 New Horizons Forum on Friday, Feb. 3, 2023, at 8:40 a.m. PT (11:40 a.m.
Htoo will participate in the session titled “Delivering Glaucoma Solutions” and will provide updates on Qlaris Bio’s plans for 2023 and the company’s novel ATP-sensitive potassium (KATP) channel modulator platform currently in development to treat a range of glaucomas, including normal tension glaucoma (NTG), primary open-angle glaucoma (POAG), and glaucoma related to rare diseases such as Sturge-Weber Syndrome.
“It is an exciting time for Qlaris and the future of glaucoma therapy,” said Htoo.
I am looking forward to sharing updates on Qlaris’ program and our anticipated milestones for the coming year.”
The Glaucoma 360 New Horizons Forum is hosted by the Glaucoma Research Foundation and brings together clinical, industry, financial, and FDA leaders to discuss research innovation and advances in glaucoma treatment.